Biomaxima (FRA:944) Cyclically Adjusted Revenue per Share: €4.08 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:944 Biomaxima SA FRA:944
59 GF Score
Price €1.97
GF Value €2.90
! 4 Warning Signs
View Full Analysis

What is Biomaxima Cyclically Adjusted Revenue per Share?

Biomaxima FRA:944 -0.30% 59 Cyclically Adjusted Revenue per Share is €4.08 as of Mar. 2026. GuruFocus rates FRA:944 with a GF Score™ of 59/100 and a GF Value™ of €2.90. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biomaxima's adjusted revenue per share for the three months ended in Mar. 2026 was €0.795. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €4.08 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Biomaxima's average Cyclically Adjusted Revenue Growth Rate was 5.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biomaxima was 17.40% per year. The lowest was 5.80% per year. And the median was 11.60% per year.

As of today (2026-09-16), Biomaxima's current stock price is €1.97. Biomaxima's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €4.08. Biomaxima's Cyclically Adjusted PS Ratio of today is 0.48.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biomaxima was 4.55. The lowest was 0.51. And the median was 1.05.


Biomaxima  (FRA:944) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biomaxima's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.97/4.078
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biomaxima was 4.55. The lowest was 0.51. And the median was 1.05.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biomaxima Cyclically Adjusted Revenue per Share Related Terms


Biomaxima Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Biomaxima's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomaxima Cyclically Adjusted Revenue per Share Chart

Biomaxima Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.40 3.25 3.45 3.66 3.81

Biomaxima Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.87 3.89 3.92 3.95 4.08

FRA:944 vs TMO, DHR, NTRA: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Biomaxima's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomaxima Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biomaxima's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biomaxima's Cyclically Adjusted PS Ratio falls into.


FRA:944
59GF Score
Biomaxima SA FRA:944
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomaxima Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biomaxima's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.795/163.0700*163.0700
=0.795

Current CPI (Mar. 2026) = 163.0700.

Biomaxima Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.407 99.552 0.667
201609 0.374 99.064 0.616
201612 0.661 100.366 1.074
201703 0.484 101.018 0.781
201706 0.489 101.180 0.788
201709 0.508 101.343 0.817
201712 0.510 102.564 0.811
201803 0.485 102.564 0.771
201806 0.486 103.378 0.767
201809 0.452 103.378 0.713
201812 0.516 103.785 0.811
201903 0.465 104.274 0.727
201906 0.489 105.983 0.752
201909 0.418 105.983 0.643
201912 0.546 107.123 0.831
202003 0.418 109.076 0.625
202006 0.845 109.402 1.260
202009 0.732 109.320 1.092
202012 1.190 109.565 1.771
202103 1.310 112.658 1.896
202106 0.713 113.960 1.020
202109 0.711 115.588 1.003
202112 1.118 119.088 1.531
202203 4.545 125.031 5.928
202206 1.147 131.705 1.420
202209 0.619 135.531 0.745
202212 0.628 139.113 0.736
202303 0.539 145.950 0.602
202306 0.563 147.009 0.625
202309 0.618 146.113 0.690
202312 0.720 147.741 0.795
202403 0.635 149.044 0.695
202406 0.691 150.997 0.746
202409 0.722 153.439 0.767
202412 0.880 154.660 0.928
202503 0.867 157.021 0.900
202506 0.722 157.509 0.747
202509 0.842 158.000 0.869
202512 0.995 158.320 1.025
202603 0.795 163.070 0.795

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €4.08 mean?
Biomaxima (FRA:944) has a Cyclically Adjusted Revenue per Share of €4.08 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biomaxima and its competitors.
Is Biomaxima's Cyclically Adjusted Revenue per Share too high?
Biomaxima's current Cyclically Adjusted Revenue per Share is €4.08. Overall, Biomaxima has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Biomaxima's Cyclically Adjusted Revenue per Share compare to TMO and DHR?
Biomaxima's Cyclically Adjusted Revenue per Share of €4.08 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biomaxima and its competitors. Biomaxima's current Cyclically Adjusted Revenue per Share is €4.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomaxima stock overvalued right now?
Biomaxima (FRA:944) has a current Cyclically Adjusted Revenue per Share of €4.08. The stock's GF Value™ is €2.90, compared to a current price of €1.97 — trading 32.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €4.08. Biomaxima's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Biomaxima (FRA:944), the current Cyclically Adjusted Revenue per Share is €4.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biomaxima (FRA:944) Overvalued in 2026?

Based on GuruFocus' analysis, Biomaxima stock appears to be undervalued. The current stock price of €1.97 is trading 32.1% below its estimated GF Value™ of €2.90.

Key valuation signals for FRA:944:

  • Cyclically Adjusted Revenue per Share: €4.08
  • GF Value™: €2.90 vs. price of €1.97 (32.1% below fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the FRA:944 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biomaxima Business Description

Other Exchanges BMX:Poland
Address 5 Vetterow Street, Lublin, POL, 20-277
BioMaxima SA is a Polish company operating in the market of laboratory diagnostics. It is a manufacturer of microbiological substrates as well as a wide range of reagents and diagnostic equipment. The company is also a distributor of products of recognized multinational diagnostic companies such as: Accelerate Diagnostics, Nova Biomedical, PHC Group, Technoclone, Kabe and Biolog.
59GF Score

Get the complete analysis for FRA:944

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.97
Price
€2.90
GF Value